Literature DB >> 9792842

Cross-clade-specific cytotoxic T lymphocytes in HIV-1-infected children.

F Buseyne1, M L Chaix, B Fleury, O Manigart, O Manigard, M Burgard, S Blanche, C Rouzioux, Y Rivière.   

Abstract

We studied cytotoxic T lymphocyte (CTL) cross-reactivity between human immunodeficiency virus type 1 (HIV-1) subtypes within a group of infants infected with either HIV-1 B or non-B clade. Fifteen children were infected with a clade B virus. Nine were infected with non-B virus, including two clade A, four clade D, two clade F, and one clade G. CTL activities from in vitro activated peripheral blood mononuclear cells were tested against autologous cell line infected with recombinant vaccinia viruses encoding for Env, Gag, Pol, or Nef proteins from a clade A or B isolate. HIV-1-specific CTL elicited from infection with clade B virus could lyse targets expressing clade A proteins, and vice versa. In infants with positive CTL responses, cross-clade recognition was predominant and was detected within 88% of the Pol, 83% of the Nef, 67% of the Gag, and 55% of the Env responders. Longitudinal studies showed that CTL cross-reactivity to both B and A targets was stable for several years. Elicitation of CTL reactivities capable of elimination of virus-infected cells is an important goal for the development of an efficient AIDS vaccine. The significant cross-reactivity of CTL shown in this study supports the concept that vaccines developed using a single-clade immunogen may be applicable to induce broadly reactive T cell responses. Copyright 1998 Academic Press

Entities:  

Mesh:

Year:  1998        PMID: 9792842     DOI: 10.1006/viro.1998.9373

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  14 in total

1.  Fine specificity and cross-clade reactivity of HIV type 1 Gag-specific CD4+ T cells.

Authors:  Philip J Norris; Howell F Moffett; Christian Brander; Todd M Allen; Kristin M O'Sullivan; Lisa A Cosimi; Daniel E Kaufmann; Bruce D Walker; Eric S Rosenberg
Journal:  AIDS Res Hum Retroviruses       Date:  2004-03       Impact factor: 2.205

2.  Patient-specific cytotoxic T-lymphocyte cross-recognition of naturally occurring variants of a human immunodeficiency virus type 1 (HIV-1) p24gag epitope by HIV-1-infected children.

Authors:  F Buseyne; M L Chaix; C Rouzioux; S Blanche; Y Rivière
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

3.  Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults.

Authors:  Ouzama Nicholson; Fay DiCandilo; James Kublin; Xiao Sun; Erin Quirk; Michelle Miller; Glenda Gray; Jean Pape; Michael N Robertson; Devan V Mehrotra; Steven Self; Katherine Turner; Jorge Sanchez; Punnee Pitisuttithum; Ann Duerr; Sheri Dubey; Lisa Kierstead; Danilo Casimiro; Scott M Hammer For The Merck V/Hiv Vaccine Trials Network Study Team
Journal:  AIDS Res Hum Retroviruses       Date:  2010-11-23       Impact factor: 2.205

4.  T cell cross-reactivity and conformational changes during TCR engagement.

Authors:  Jean K Lee; Guillaume Stewart-Jones; Tao Dong; Karl Harlos; Kati Di Gleria; Lucy Dorrell; Daniel C Douek; P Anton van der Merwe; E Yvonne Jones; Andrew J McMichael
Journal:  J Exp Med       Date:  2004-12-06       Impact factor: 14.307

5.  Restricted genetic diversity of HIV-1 subtype C envelope glycoprotein from perinatally infected Zambian infants.

Authors:  Hong Zhang; Damien C Tully; Federico G Hoffmann; Jun He; Chipepo Kankasa; Charles Wood
Journal:  PLoS One       Date:  2010-02-18       Impact factor: 3.240

Review 6.  Human immunodeficiency virus vaccines.

Authors:  Paul Goepfert; Anju Bansal
Journal:  Infect Dis Clin North Am       Date:  2014-10-05       Impact factor: 5.982

7.  Functional properties and epitope characteristics of T-cells recognizing natural HIV-1 variants.

Authors:  U Malhotra; J Nolin; H Horton; F Li; L Corey; J I Mullins; M J McElrath
Journal:  Vaccine       Date:  2009-09-09       Impact factor: 3.641

8.  Comprehensive screening reveals strong and broadly directed human immunodeficiency virus type 1-specific CD8 responses in perinatally infected children.

Authors:  M E Feeney; K A Roosevelt; Y Tang; K J Pfafferott; K McIntosh; S K Burchett; C Mao; B D Walker; P J R Goulder
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

9.  Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa.

Authors:  Pontiano Kaleebu; Harr Freeya Njai; Lei Wang; Norman Jones; Isaac Ssewanyana; Paul Richardson; Kenneth Kintu; Lynda Emel; Philippa Musoke; Mary Glenn Fowler; San-San Ou; J Brooks Jackson; Laura Guay; Philip Andrew; Lynn Baglyos; Huyen Cao
Journal:  J Acquir Immune Defic Syndr       Date:  2014-03-01       Impact factor: 3.731

10.  The effect of HLA polymorphisms on the recognition of Gag epitopes in HIV-1 CRF01_AE infection.

Authors:  Busarawan Sriwanthana; Masahiko Mori; Mari Tanaka; Sei Nishimura; Toshiyuki Miura; Panita Pathipvanich; Pathom Sawanpanyalert; Koya Ariyoshi
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.